Cytokinetics | CYTK - Selling And Administration Expenses

Stock Price
75.85
Daily Change
-2.79 -3.55%
Monthly
15.94%
Yearly
144.68%
Q2 Forecast
75.32

Cytokinetics reported $104.9M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Arca Biopharma USD 2.23M 1.08M Dec/2025
Bayer EUR 3.7B 356M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Brainstorm Cell Therapeutics USD 1.39M 326K Dec/2025
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Cytokinetics USD 104.9M 13.17M Mar/2026
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Exelixis USD 139.6M 16.58M Mar/2026
Geron USD 35.42M 6.24M Mar/2026
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026